BRCA1在前列腺癌组织中的表达及临床意义

BRCA1 expression in prostate carcinoma and its clinical significance

目的探讨乳腺癌易感基因1(breast cancer susceptibility gene-1,BRCA1)在前列腺癌组织中的表达及临床意义。方法采用SP免疫组化法检测46例前列腺癌组织及14例癌旁组织中BRCA1的表达,分析BRCA1表达与前列腺癌临床病理特征的关系。结果 14例前列腺癌旁组织中BRCA1阳性表达率为78.6%(11/14),46例前列腺癌组织中BRCA1阳性表达率为45.7%(21/46),两者比较差异有统计学意义(P<0.05)。BRCA1表达与前列腺癌家族史、Gleason评分和TMN分期有关(P<0.05),与年龄和前列腺特异性抗原(prostate specific antigen,PSA)浓度无关(P>0.05)。结论 BRCA1在前列腺癌组织中低表达,且随肿瘤恶性程度增加其表达降低,提示检测BRCA1蛋白对前列腺癌辅助诊断及预后判断有一定参考价值。

Objective To analyze breast cancer susceptibility gene-1 （BRCA1） expression and its clinical significance in prostate carcinoma. Methods BRCA1 expression was analyzed using immunohistochemistry in 46 prostate carcinoma tissue sections and 14 adjacent normal tissue sections. Possible relationships were explored between BRCA1 expression and clinicopathological variables. Results Rate of BRCA1 positivity was 78.6% for adjacent normal tissue, but only 45.7% for prostate carcinoma. BRCA1 expression levels were significantly lower in prostate carcinoma tissues than in adjacent normal tissues （P〈0.05）. BRCA1 expression level correlated with family history, Gleason classification and TMN stage （P〈0.05）, but not with age or prostate-specific antigen （PSA） （P〉0.05）. Conclusion Prostate carcinoma is associated with lower BRCA1 expression,and lower expression may correlate with greater tumor malignancy. BRCA 1 may be a useful diagnostic and prognostic biomarker in prostate cancer.